Five Prime Therapeutics Inc: Phill Gross And Robert Atchinson’s Adage Capital Partners Gp. Makes Purchase

February 14, 2018 - By Adrian Mccoy

 Five Prime Therapeutics Inc: Phill Gross And Robert Atchinson's Adage Capital Partners Gp. Makes Purchase

Investors sentiment increased to 1.04 in 2017 Q3. Its up 0.34, from 0.7 in 2017Q2. It improved, as 14 investors sold Five Prime Therapeutics, Inc. shares while 34 reduced holdings. 18 funds opened positions while 32 raised stakes. 23.96 million shares or 0.77% more from 23.78 million shares in 2017Q2 were reported.

Granite Point Capital Limited Partnership holds 50,000 shares. Quantbot Techs Limited Partnership invested in 0% or 220 shares. Schroder Investment Group invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). 601,000 were accumulated by Eventide Asset Management Ltd Liability. Moreover, Artal Gru has 0.04% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 50,000 shares. Barclays Public Ltd Co accumulated 0% or 10,115 shares. Wells Fargo Mn, a California-based fund reported 185,382 shares. 325 are held by Nelson Roberts Investment Advsrs Ltd Liability Co. Moreover, Ameritas Invest Prns has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 2,330 shares. Renaissance Ltd has invested 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Teachers Retirement System Of The State Of Kentucky reported 0.02% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Swiss State Bank reported 0% stake. State Board Of Administration Of Florida Retirement Sys stated it has 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Doheny Asset Mngmt Ca invested in 0.12% or 6,150 shares. Victory Capital Mgmt owns 532,640 shares.

Since September 28, 2017, it had 0 buys, and 2 selling transactions for $148,468 activity.

The New Phill Gross And Robert Atchinson’s Adage Capital Partners Gp. Holding in Five Prime Therapeutics Inc

Adage Capital Partners Gp. reported SC 13G/A form with the SEC for Five Prime Therapeutics Inc. Access it here: 000090266418000976. As reported by Phill Gross And Robert Atchinson’s Adage Capital Partners Gp., the filler owns 28930241% or 1,300,000 shares of the Health Care–company.

Five Prime Therapeutics Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Phill Gross And Robert Atchinson’s Adage Capital Partners Gp.’s positive view for Five Prime Therapeutics Inc.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Phill Gross And Robert Atchinson’s Adage Capital Partners Gp.’s portfolio is in the sector.

Five Prime Therapeutics Inc Institutional Sentiment

Filings show 105 investors own Five Prime Therapeutics Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 6735162. 25908021 were owned by these investors. 16 funds opened new Five Prime Therapeutics Inc stakes, 39 increased positions. There were 16 that closed positions and 34 reduced them.

2 investors had the stock in their top 10. Some are: .

Armistice Capital Llc is an investor bullish on Five Prime Therapeutics Inc, owning 506000 shares as of Q3 2015 for 2.66% of its portfolio. Ecor1 Capital Llc owns 149000 shares or 1.04% of its portfolio. NY Ghost Tree Capital Llc have 3.46% of its portfolio for 500000 shares. Further, Rtw Investments Llc reported stake worth 3.41% of its portfolio. The CT Great Point Partners Llc owns 1226785 shares. Five Prime Therapeutics Inc is 7.47% of its portfolio.

Business Profile

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

SEC Form 13G.

Analysts await Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report earnings on February, 22. They expect $-1.29 earnings per share, down 76.71 % or $0.56 from last year’s $-0.73 per share. After $-1.54 actual earnings per share reported by Five Prime Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -16.23 % EPS growth.

The stock increased 2.35% or $0.44 during the last trading session, reaching $19.17. About 493,608 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 30.56% since February 14, 2017 and is downtrending. It has underperformed by 47.26% the S&P500.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $651.99 million. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Ratings Coverage

Among 10 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Five Prime Therapeutics has $75 highest and $33 lowest target. $51.67’s average target is 169.54% above currents $19.17 stock price. Five Prime Therapeutics had 21 analyst reports since July 31, 2015 according to SRatingsIntel. BMO Capital Markets maintained Five Prime Therapeutics, Inc. (NASDAQ:FPRX) on Monday, June 5 with “Hold” rating. The rating was initiated by Citigroup on Tuesday, October 25 with “Buy”. The firm has “Sell” rating given on Friday, August 21 by Zacks. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has “Buy” rating given on Friday, July 31 by Citigroup. The firm has “Outperform” rating given on Monday, October 19 by Oppenheimer. RBC Capital Markets maintained Five Prime Therapeutics, Inc. (NASDAQ:FPRX) on Monday, November 6 with “Buy” rating. As per Tuesday, November 7, the company rating was maintained by BMO Capital Markets. The rating was maintained by Wells Fargo with “Outperform” on Friday, December 4. Jefferies maintained the stock with “Buy” rating in Monday, September 11 report. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has “Market Perform” rating given on Tuesday, April 12 by BMO Capital Markets.

More notable recent Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news were published by: Globenewswire.com which released: “Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global …” on February 08, 2018, also Globenewswire.com with their article: “Five Prime Therapeutics Announces Closing of Upsized Public Offering” published on January 29, 2018, Nasdaq.com published: “Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 …” on February 08, 2018. More interesting news about Five Prime Therapeutics, Inc. (NASDAQ:FPRX) were released by: Globenewswire.com and their article: “Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb …” published on January 25, 2018 as well as Globenewswire.com‘s news article titled: “Five Prime Announces Proposed Public Offering of Common Stock” with publication date: January 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: